Health & Fitness
Tue, February 10, 2009Mon, February 9, 2009Sun, February 8, 2009Fri, February 6, 2009Thu, February 5, 2009Wed, February 4, 2009Tue, February 3, 2009Mon, February 2, 2009Sun, February 1, 2009Sat, January 31, 2009Fri, January 30, 2009Thu, January 29, 2009Wed, January 28, 2009AVANIR to Present at the 11th Annual BIO CEO & Investor Conference
Published in Health and Fitness on Tuesday, February 3rd 2009 at 16:08 GMT, Last Modified on 2009-02-03 16:09:27 by Market Wire
ALISO VIEJO, Calif.--([ BUSINESS WIRE ])--AVANIR Pharmaceuticals (NASDAQ: AVNR)today announced that Keith Katkin, President and Chief Executive Officer, will present at the 11th Annual BIO CEO & Investor Conference on Tuesday, February 10 at 9:30 a.m. Eastern time (6:30 a.m. Pacific time). This conference will be held at the Waldorf Astoria Hotel in New York. The BIO CEO & Investor Conference is the largest conference focused on publicly traded biotechnology companies and provides participating companies with the opportunity to present to institutional investors, industry analysts, and business development and partnering executives. For more information visit [ www.ceo.bio.org ].
A live audio webcast of the presentation will be available by visiting AVANIR's website at [ www.avanir.com ]. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary audio software. An archive of Mr. Katkin's presentation at the BIO CEO & Investor Conference will be available on the Company's website for 30 days.
About AVANIR
AVANIR Pharmaceuticals is focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, inflammation, and infectious diseases. AVANIR's lead product candidate, Zenvia™, is being developed for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at [ www.avanir.com ] and further information about pseudobulbar affect can be found at [ www.PBAinfo.org ].
To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website:
